1 domain / 2 areas / 1 specialization
Leafy Tunnel
Data updated
Leafy Tunnel is a venture capital firm focused on alternative medicine, with an emphasis on medicinal cannabis and psychedelics. Its public-facing materials describe it as an early-stage investor and place its headquarters in London, United Kingdom.
In the psychedelic ecosystem, Leafy Tunnel matters because it has publicly positioned itself around medical cannabis and global medical psychedelics opportunities, with a stated focus on Seed and Series A investing. Public funding coverage shows it led Lyphe Group’s £5m Series A round in 2022, supporting expansion across Europe.
Investor Context
Venture CapitalInvestment Context
This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage signals include Seed, Series A/B, and Growth / Late Stage. Public focus areas include Drug Development.
Leafy Tunnel presents itself as an early-stage venture firm backing alternative medicine companies, especially those developing medicinal cannabis and psychedelic therapies for mental health and pain-related conditions. Its stated strategy is centered on the European market, and public funding coverage indicates it has participated in growth-oriented medical cannabis financing, including a lead role in Lyphe Group’s 2022 Series A round. The firm’s psychedelic relevance is strongest at the intersection of drug development, patient access, and adjacent medical cannabis infrastructure.
Investor Type
Venture Capital Fund
Geographic Scope
Global
Psychedelic Focus
Psychedelic-Adjacent Focus
Engagement
Active
Investment Stage Focus
Investment Focus Areas
Quick Facts
- HQ
- London, SW1E 5JL; 100 Victoria Street, United Kingdom
- Website
- Visit